KEAP1 and cancer: A recent pan-cancer analysis has revealed that tumors with KEAP1 mutations have a poor response to ICB with a low level of T cell-inflamed GEP, and the immunomodulatory effects of KEAP1 mutations appear to be specific to cancer types, especially in LUAD and LUSC 97.